



07-10-2016

10:15 - 11:45	Type: Educational session Title: Cancer Immunotherapy (CIT): What every oncologist should know Chair(s): S. van der Burg, NL	Vienna
10:15 - 10:30	Back to the basics <u>S. van der Burg</u> , NL	
10:30 - 10:55	Cancer vaccines: Can we make them work? <u>C.(. Melief</u> , NL	
10:55 - 11:20	T cell therapy: For whom and when? <u>I.M. Svane</u> , DK	
11:20 - 11:45	Immune checkpoints: Do we really know how they work? <u>I. Melero</u> , ES	
12:00 - 13:20	Type: Opening session Title: Opening Session and Award lectures	Copenhagen
14:00 - 15:30	Type: Proffered Paper session Title: Proffered papers session 1	Copenhagen
14:00 - 15:30	Type: Educational session Title: Metastatic colorectal cancer: Providing the continuum of care Chair(s): C. Tournigand, FR	Vienna
14:00 - 14:30	What can be done beyond first line targeted agents: Switch or continue? <u>D. Arnold</u> , DE	
14:30 - 15:00	Re-introduction: Is it a valid concept? <u>C. Tournigand</u> , FR	
15:00 - 15:30	On-treatment biomarkers: Do they help to define the best sequence? <u>C. Montagut</u> , ES	



14:00 - 15:30	Type: Educational session Title: New developments in the management of ER-positive metastatic breast cancer Chair(s): <u>G. Curigliano</u> , IT	Stockholm
14:00 - 14:30	Unlocking the pathways of endocrine resistance <u>G. Curigliano</u> , IT	
14:30 - 15:00	Current and emerging treatment approaches: An embarrassment of riches? <u>N. Harbeck</u> , DE	
15:00 - 15:30	Minimising the toxicities of targeted therapies <u>T. Bachelot</u> , FR	
14:00 - 15:30	Type: Proffered Paper session Title: Proffered papers session 2	Madrid
14:00 - 15:30	Type: Educational session Title: Imaging in metastatic prostate cancer Chair(s): <u>F. Lecouvet</u> , BE	Rome
14:00 - 14:30	The role of whole body MRI <u>F. Lecouvet</u> , BE	
14:30 - 15:00	The role of PET/CT <u>U. Haberkorn</u> , DE	
15:00 - 15:30	Radiographic progression free survival: A new biomarker of response to treatment? <u>M. Morris</u> , US	
14:00 - 15:30	Type: Joint Symposium Title: ESMO Joint Symposium 1	Athens
14:00 - 15:30	Type: Joint Symposium Title: ESMO Joint Symposium 2	Helsinki



14:00 - 15:30	Type: Educational session Title: Wind of change: Challenges in neuro-oncology in 2016 Chair(s): A. Brandes, IT; M. Brada, GB	Brussels
14:00 - 14:30	The new WHO classification: Is molecular diagnosis ready for prime time? <u>P. Wesseling</u> , NL	
14:30 - 15:00	Newly diagnosed and recurrent glioblastoma: Where are we going? <u>A. Brandes</u> , IT	
15:00 - 15:30	Standard and future approaches in the treatment of rare CNS tumours <u>M. Brada</u> , GB	
14:00 - 15:30	Type: Joint Symposium Title: ESMO Joint Symposium 3	Berlin
14:00 - 15:30	Type: Special Session Title: Communication findings of clinical trials: The first 12 months from analysis	Bern
14:00 - 14:05	Introduction	
14:05 - 14:20	Disseminating results: What are we trying to achieve and who needs to hear?	
14:20 - 14:35	What, when and how patients and the public want to know: New results and implications for practice	
14:35 - 14:50	The role of the press office and the role of the media	
14:50 - 15:05	How clinical trial data do or do not lead to changes in practice: The perspective of the regulator	
15:05 - 15:20	How clinical trial data leads to changes in practice: The perspective of the cost-effectiveness body	
15:20 - 15:30	Conclusions	
14:00 - 15:30	Type: Proffered Paper session Title: Proffered papers session 3	Oslo



14:00 - 14:30	Type: Patient Advocacy Track Title: Welcome	Warsaw
14:00 - 14:15	Welcome by ESMO	
14:15 - 14:30	Welcome by the ESMO PAWG Chair	
14:45 - 15:45	Type: Patient Advocacy Track Title: Knowledge is power	Warsaw
14:45 - 15:00	Why education matters and how social media are changing advocacy	
15:00 - 15:15	From research on patients to patient researchers	
15:15 - 15:30	How to educate yourself in research and development- EUPATI the European Patient Academy for Therapeutical Innovation	
15:30 - 15:45	Discussion	
16:00 - 17:30	Type: Proffered Paper session Title: Proffered papers session 4	Copenhagen
16:00 - 17:30	Type: Educational session Title: Emerging concepts in daily management of urothelial tumours Chair(s): A. Bamias, GR	Oslo
16:00 - 16:30	How to select systemic therapy in bladder cancer <u>A. Bamias</u> , GR	
16:30 - 17:00	How to interpret genomic reports in the management of urothelial malignancies <u>J. Catto</u> , GB	
17:00 - 17:30	Targeted therapies in urothelial malignancies <u>J. Rosenberg</u> , US	



16:00 - 17:30	Type: Educational session Title: What is new in liver cancer Chair(s): M. Ducreux, FR; J. Llovet, US	Vienna
16:00 - 16:30	The biology of liver cancer <u>J. Zucman-Rossi</u> , FR	
16:30 - 17:00	Stage-dependent management of HCC and news in systemic treatment <u>J. Llovet</u> , US	
17:00 - 17:30	New developments in locoregional treatment <u>J. Ricke</u> , DE	
16:00 - 17:30	Type: Proffered Paper session Title: Proffered papers session 5	Stockholm
16:00 - 17:30	Type: Special Symposium Title: Adapting clinical trials to tumour biology: Shooting at a moving target Chair(s): A. Bardelli, IT	Madrid
16:00 - 16:05	Introduction	
16:05 - 16:25	What have we learned from failures? <u>E. Dean</u> , GB	
16:25 - 16:45	Master protocols and basket trials: Have we found the answer? <u>K. Flaherty</u> , US	
16:45 - 17:05	Modulating responses using CtDNA <u>A. Bardelli</u> , IT	
17:05 - 17:25	New clinical trial design <u>S. Galbraith</u> , GB	
17:25 - 17:30	Conclusions and clinical perspectives <u>A. Bardelli</u> , IT	



16:00 - 17:30	Type: Educational session Title: Optimal treatment of stage III NSCLC Chair(s): J. Vansteenkiste, BE	Rome
16:00 - 16:30	Which induction therapy for potentially resectable cases? <u>W. Eberhardt</u> , DE	
16:30 - 17:00	Which systemic therapy in concurrent chemoradiotherapy? <u>J. Vansteenkiste</u> , BE	
17:00 - 17:30	Which radiotherapy in concurrent chemoradiotherapy? <u>S. Senan</u> , NL	
16:00 - 17:30	Type: Joint Symposium Title: ESMO Joint Symposium 4	Athens
16:00 - 17:30	Type: Special Session Title: Early detection of cachexia, multimodal intervention and results Chair(s): K. Jordan, DE; M. Aapro, CH	Helsinki
16:00 - 16:20	The role of nutritional support during radio-/chemotherapy <u>J. Arends</u> , DE	
16:20 - 16:40	New drugs to treat patients with cancer anorexia cachexia syndrome <u>C. Ripamonti</u> , IT	
16:40 - 17:00	The evidence of physical activity interventions during radio-/chemotherapy <u>M. Maddocks</u> , GB	
17:00 - 17:20	Elderly patients: Often malnourished <u>M. Aapro</u> , CH	
17:20 - 17:30	General discussion: How to integrate cachexia management in routine cancer care	
16:00 - 17:30	Type: Joint Symposium Title: ESMO Joint Symposium 5	Brussels
16:00 - 17:30	Type: Joint Symposium Title: ESMO Joint Symposium 6	Berlin
16:00 - 17:30	Type: Proffered Paper session Title: Proffered papers session 6	Bern



16:15 - 17:15	Type: Patient Advocacy Track Title: Patient networks driving research	Warsaw
16:15 - 16:30	Research priority setting: The James Lind Alliance experience	
16:30 - 16:45	Research strategy development for PA groups	
16:45 - 17:00	Discussion	
17:30 - 18:30	Type: Patient Advocacy Track Title: Cancer and pregnancy	Warsaw
17:30 - 17:45	Despite cancer: Challenges and public awareness	
17:45 - 18:00	The clinican's perspective on pregnancies in cancer	
18:00 - 18:15	A patient-run cancer and pregnancy registry	
18:15 - 18:30	Discussion	
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Oslo
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Vienna
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Stockholm
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Madrid
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Rome
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Athens



18:00 - 20:00 Type: Industry Satellite Symposium Helsinki
 Title: Industry Satellite Symposium or ESMO Colloquium

18:00 - 20:00 Type: Industry Satellite Symposium Brussels
 Title: Industry Satellite Symposium or ESMO Colloquium

18:00 - 20:00 Type: Industry Satellite Symposium Berlin
 Title: Industry Satellite Symposium or ESMO Colloquium

18:00 - 20:00 Type: Industry Satellite Symposium Bern
 Title: Industry Satellite Symposium or ESMO Colloquium

18:00 - 20:00 Type: Industry Satellite Symposium Lisbon
 Title: Industry Satellite Symposium or ESMO Colloquium

18:00 - 20:00 Type: Industry Satellite Symposium Zagreb
 Title: Industry Satellite Symposium or ESMO Colloquium

08-10-2016

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Brussels
 Title: Minimising the complications of ADT and bone disease in prostate cancer

08:00 - 08:30 Minimising the complications of ADT and bone disease in prostate cancer
M. Smith, US

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Berlin
 Title: Fragile patients with non-metastatic lung cancer: Facts and myths

08:00 - 08:30 Fragile patients with non-metastatic lung cancer: Facts and myths
J. van Loon, NL

08:30 - 09:00 Discussion



08:00 - 09:00	Type: Challenge Your Expert (CYE) session Title: Novel criteria for diagnosing multiple myeloma and their therapeutic implications	Bern
08:00 - 08:30	Novel criteria for diagnosing multiple myeloma and their therapeutic implications <u>J. San Miguel</u> , ES	
08:30 - 09:00	Discussion	
08:00 - 09:00	Type: Challenge Your Expert (CYE) session Title: Primary and secondary resistance to targeted therapy and immunotherapy	Lisbon
08:00 - 08:30	Primary and secondary resistance to targeted therapy and immunotherapy <u>J. Engelman</u> , US	
08:30 - 09:00	Discussion	
08:00 - 09:00	Type: Challenge Your Expert (CYE) session Title: The revolution of molecular diagnosis in anaplastic gliomas	Zagreb
08:00 - 08:30	The revolution of molecular diagnosis in anaplastic gliomas <u>W. Wick</u> , DE	
08:30 - 09:00	Discussion	
08:15 - 09:15	Type: Controversy session Title: Controversy session 1	Rome
09:00 - 10:30	Type: Proffered Paper session Title: Proffered papers session 7	Copenhagen



09:00 - 10:30	Type: Educational session Title: The neoadjuvant approach in the multidisciplinary setting Chair(s): M. Colleoni, IT; S. Loibl, DE	Stockholm
09:00 - 09:30	Systemic neoadjuvant treatment <u>S. Loibl</u> , DE	
09:30 - 10:00	Surgical challenges after neoadjuvant therapy <u>I. Rubio</u> , ES	
10:00 - 10:30	The impact of tumour stage and response on radiotherapy indications <u>J. Bernier</u> , CH	
09:00 - 10:30	Type: Proffered Paper session Title: Proffered papers session 8	Madrid
09:00 - 10:30	Type: Special Symposium Title: Whither immunotherapy? Chair(s): M. Colombo, IT	Oslo
09:00 - 09:05	Introduction	
09:05 - 09:25	Tumour landscape: Clues for new targets <u>J. Galon</u> , FR	
09:25 - 09:45	Converting a non-immunogenic into an immunogenic tumour <u>T. Gajewski</u> , US	
09:45 - 10:05	Inflamed phenotype and immunotherapy: The H&N case <u>T. Seiwert</u> , US	
10:05 - 10:25	Combining immunotherapy: (ir)rational choices <u>J. Larkin</u> , GB	
10:25 - 10:30	Conclusions and clinical perspectives <u>M. Colombo</u> , IT	



09:15 - 10:45	Type: Special Symposium Title: Lung cancer early detection and prevention Chair(s): G. Veronesi, IT	Vienna
09:15 - 09:20	Introduction	
09:20 - 09:40	The NELSON trial <u>H. de Koning</u> , NL	
09:40 - 10:00	How to implement the NELSON trial <u>S. Janes</u> , GB	
10:00 - 10:20	Defining risk populations with biomarkers <u>G. Veronesi</u> , IT	
10:20 - 10:40	Smoking cessation <u>H. Ashraf</u> , NO	
10:40 - 10:45	Conclusions and clinical perspectives <u>G. Veronesi</u> , IT	
09:15 - 10:45	Type: Special Session Title: Will we ever conquer resistance? Chair(s): D. Peeper, NL	Helsinki
09:15 - 09:20	Introduction <u>D. Peeper</u> , NL	
09:20 - 09:40	Tumour evolution under the selective pressure of treatment <u>C. Swanton</u> , GB	
09:40 - 10:00	Mechanisms of resistance mediated by the tumour stroma	
10:00 - 10:20	New approaches to BRAF resistant disease <u>R. Marais</u> , GB	
10:20 - 10:40	What can we learn from single patients? <u>D. Peeper</u> , NL	
10:40 - 10:45	Conclusions and clinical perspectives	



09:15 - 10:45	Type: Patient Advocacy Track Title: Accessing innovative treatments in Europe: Managed entry/ risk sharing schemes for pharmaceuticals	Zagreb
09:15 - 09:30	Introduction to Managed Entry Schemes	
09:30 - 09:45	The Early Access to Medicines Scheme (EAMS) in the UK	
09:45 - 10:00	The Italian Pay-for-Performance Scheme	
10:00 - 10:15	The Dutch experience: Ipilimumab in advanced melanoma	
10:15 - 10:30	Patient advocacy involvement	
10:30 - 10:45	Discussion: How to get involved	
09:30 - 10:30	Type: Controversy session Title: Controversy session 2	Rome
09:30 - 10:30	Type: Multidisciplinary patient cases Title: Pulmonary NETs Chair(s): J. Yao, US	Athens
09:30 - 09:40	The grey zone in between intermediate and high grade NENs: A particular case <u>G. Rindi</u> , IT	
09:40 - 09:50	The minimal surgical approach for lung carcinoids: Pros and cons	
09:50 - 10:00	The evolving landscape of systemic therapy for well differentiated neuroendocrine tumours of the lung <u>J. Yao</u> , US	
10:00 - 10:30	Discussion	
09:30 - 10:30	Type: Poster Discussion session Title: Poster discussion session 1	Brussels



09:30 - 10:30	Type: Challenge Your Expert (CYE) session Title: Challenges in bone sarcoma	Berlin
09:30 - 10:00	Challenges in bone sarcoma <u>S. Bielack</u> , DE	
10:00 - 10:30	Discussion	
09:30 - 10:30	Type: Poster Discussion session Title: Poster discussion session 2	Bern
11:00 - 12:30	Type: Special Symposium Title: A molecular profile in NSCLC patients: How? When? Why? Chair(s): F. Blackhall, GB; F. Barlesi, FR	Copenhagen
11:00 - 11:05	Introduction <u>F. Blackhall</u> , GB	
11:05 - 11:25	Molecular profiling for precision lung cancer <u>R. Thomas</u> , DE	
11:25 - 11:45	Organisation: Local, regional and national <u>F. Barlesi</u> , FR	
11:45 - 12:05	Clinical application of serial molecular biomarker monitoring <u>S. Finn</u> , IE	
12:05 - 12:25	Getting the right drug to the right patient based upon molecular profiling <u>J.-C. Soria</u> , FR	
12:25 - 12:30	Conclusions and clinical perspectives <u>F. Barlesi</u> , FR	
11:00 - 12:30	Type: Proffered Paper session Title: Proffered papers session 9	Vienna



11:00 - 12:30 Type: Special Symposium Stockholm
Title: Genetics and epigenetics of gastric cancer: What clinicians should know
Chair(s): F. Carneiro, PT; A. Hillmer, SG

11:00 - 11:05 Introduction
A. Hillmer, SG

11:05 - 11:25 How to detect and manage familial and hereditary gastric cancer
F. Carneiro, PT

11:25 - 11:45 Genetics of gastric cancer: Clinical implications
I. Chau, GB

11:45 - 12:05 DNA methylation and epigenetic changes in gastric cancer: From bench to bedside
T. Ushijima, JP

12:05 - 12:25 As a clinician, what do I make of this information?
P. Pfeiffer, DK

12:25 - 12:30 Conclusion
F. Carneiro, PT

11:00 - 12:30 Type: Special Symposium Madrid
Title: Optimal combination and sequencing strategies in melanoma
Chair(s): P. Ascierto, IT; R. Dummer, CH

11:00 - 11:05 Introduction
R. Dummer, FR

11:05 - 11:25 Rationale for combining
P. Ascierto, IT

11:25 - 11:45 Rationale for sequencing
C. Robert, FR

11:45 - 12:05 Can biomarkers help make the decision?
A. Ribas, US

12:05 - 12:25 A closer look at the current guidelines on sequencing and combination
P. Lorigan, GB

12:25 - 12:30 Conclusions and clinical perspectives
P. Ascierto, IT



11:00 - 12:30	Type: Joint Symposium Title: ESMO Joint Symposium 7	Rome
11:00 - 12:00	Type: Multidisciplinary patient cases Title: Complex symptomatic RCC with bone metastasis Chair(s): V. Grünwald, DE	Athens
11:00 - 11:05	Case presentation <u>V. Grünwald</u> , DE	
11:05 - 11:15	Every patient with bone metastases should be evaluated for surgical intervention <u>A. Bex</u> , NL	
11:15 - 11:25	Local therapy should implement radiotherapy in bone disease <u>V. Khoo</u> , GB	
11:25 - 11:35	When medical treatment is just enough in bone disease <u>V. Grünwald</u> , DE	
11:35 - 12:00	Discussion	
11:00 - 12:00	Type: Challenge Your Expert (CYE) session Title: Neurotoxicities assessment, prophylaxis and treatment Chair(s): M. Fallon, GB	Helsinki
11:00 - 11:30	Neurotoxicities assessment, prophylaxis and treatment <u>L. Eckhoff</u> , DK	
11:30 - 12:00	Discussion	
11:00 - 12:30	Type: Proffered Paper session Title: Proffered papers session 11	Brussels



11:00 - 12:30	Type: Special Symposium Title: Emerging therapeutic strategies in lymphoma Chair(s): P. Johnson, GB; A. Ferreri, IT	Berlin
11:00 - 11:05	Introduction <u>A. Ferreri</u> , IT	
11:05 - 11:25	Hodgkin's Lymphoma: How to incorporate novel agents into standard care of treatment <u>P. Johnson</u> , GB	
11:25 - 11:45	CLL: Moving towards chemotherapy and free approaches <u>P. Ghia</u> , IT	
11:45 - 12:05	Mantle cell lymphoma: Impact of novel agents on treatment algorithms <u>S. Rule</u> , GB	
12:05 - 12:25	Follicular lymphoma: Novel developments beyond chemotherapy <u>C. Buske</u> , DE	
12:25 - 12:30	Conclusions and clinical perspectives <u>P. Johnson</u> , GB	
11:00 - 12:00	Type: Multidisciplinary patient cases Title: Low grade glioma: Back to the future Chair(s): M. van den Bent, NL	Bern
11:00 - 11:05	Case presentation <u>M. van den Bent</u> , NL	
11:05 - 11:15	The role of surgery in low grade gliomas: Do timing and extent of resection matter? <u>H. Duffau</u> , FR	
11:15 - 11:25	When and how treat low grade gliomas? <u>M. van den Bent</u> , NL	
11:25 - 12:00	Discussion	



11:00 - 12:00	Type: Young Oncologist Brunch Title: EMA approval process for anticancer agents: What should the oncologist know? Chair(s): M. Stribos, BE; R. Califano, GB	Lisbon
11:00 - 11:25	EMA approval process for anticancer agents: What should the oncologist know? <u>F. Pignatti</u> , GB	
11:25 - 12:00	Interactive discussion with audience	
11:00 - 12:30	Type: Proffered Paper session Title: Proffered papers session 10	Oslo
13:00 - 13:45	Type: Keynote lecture Title: The development of checkpoint inhibitors	Vienna
13:00 - 13:45	The development of checkpoint inhibitors <u>J. Allison</u> , US	
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Stockholm
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Madrid
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Rome
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Athens
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Helsinki
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Brussels
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Berlin
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Oslo



13:00 - 14:30	Type: Patient Advocacy Track Title: Disparities in cancer care	Zagreb
13:00 - 13:10	Addressing disparities in cancer care in Europe	
13:10 - 13:20	Disparities in cancer data availability: Cancer registration in Europe	
13:20 - 13:30	A step towards ensuring a Minimum Standard of Care: Ensuring availability of essential cancer drugs in Europe	
13:30 - 13:40	Disparities in access to real multidisciplinary cancer care	
13:40 - 13:50	Disparities in dealing with patients: "Discrimination" of patients minorities	
13:50 - 14:30	Panel discussion: Practical actions to be taken	
14:45 - 16:15	Type: Proffered Paper session Title: Proffered papers session 12	Copenhagen
14:45 - 16:15	Type: Educational session Title: Difficult decisions in gynaecological oncology Chair(s): I. Ray-Coquard, FR; A. Poveda, ES	Oslo
14:45 - 15:15	Adjuvant therapy of endometrial cancer <u>C. Creutzberg</u> , NL	
15:15 - 15:45	Management of vulnerable patients with gynaecological cancers <u>G. Freyer</u> , FR	
15:45 - 16:15	Rare ovarian tumours: A special focus on sex cord and germ cell tumours <u>I. Ray-Coquard</u> , FR	



14:45 - 16:15	Type: Educational session Title: Hot topics in the adjuvant treatment of colorectal cancer Chair(s): R. Adams, GB; J. Taieb, FR	Vienna
14:45 - 15:15	BRAF, KRAS, MSI and gene signatures: Where are we now? <u>R. Salazar</u> , ES	
15:15 - 15:45	How best to treat adjuvant rectal cancer <u>R. Adams</u> , GB	
15:45 - 16:15	Complex colon cancer patients in the adjuvant setting <u>T. André</u> , FR	
14:45 - 16:15	Type: Proffered Paper session Title: Proffered papers session 13	Stockholm
14:45 - 16:15	Type: Educational session Title: Brain metastases: Are we ready for a paradigm shift? Chair(s): R. Stupp, CH	Madrid
14:45 - 15:15	The biology of brain metastases: What should we know? <u>M. Valiente</u> , ES	
15:15 - 15:45	Is the blood brain barrier still a limit for targeted therapies in brain metastases? <u>M. Preusser</u> , AT	
15:45 - 16:15	The treatment of brain metastases in the era of immuno-oncology <u>R. Stupp</u> , CH	
14:45 - 16:15	Type: Joint Symposium Title: ESMO Joint Symposium 8	Athens
14:45 - 16:15	Type: Joint Symposium Title: ESMO Joint Symposium 9	Brussels



15:00 - 16:00	Type: Multidisciplinary patient cases Title: Pain from bone metastases Chair(s): D. Santini, IT	Rome
15:00 - 15:10	The medical treatment of bone metastases <u>D. Santini</u> , IT	
15:10 - 15:20	The role of radiotherapy in the control of bone pain <u>P. Feyer</u> , DE	
15:20 - 15:30	Analgesic multimodal management according to risk factors of cancer pain <u>E. Kalso</u> , FI	
15:30 - 16:00	Discussion	
15:00 - 16:00	Type: Multidisciplinary patient cases Title: Precision medicine in the clinic: How do I provide it? Chair(s): C. Ferte, FR	Helsinki
15:00 - 15:10	Patient case presentation <u>P. Aftimos</u> , BE	
15:10 - 15:20	From raw data to a comprehensive genetic report <u>A. Vivancos</u> , ES	
15:20 - 15:30	From a NGS test to a clinical decision <u>C. Ferte</u> , FR	
15:30 - 16:00	Discussion	
15:00 - 16:00	Type: Poster Discussion session Title: Poster discussion session 3	Berlin
15:00 - 16:00	Type: Poster Discussion session Title: Poster discussion session 4	Bern
16:30 - 18:00	Type: Presidential Symposium Title: Presidential Symposium 1	Copenhagen



16:30 - 17:30 Type: Multidisciplinary patient cases Vienna
 Title: Definition and management of oligoprogression during treatment with TKI inhibitors
 Chair(s): E. Smit, NL

16:30 - 16:40 Practicalities and risks of biopsy
J. Barry, IE

16:40 - 16:50 Optimal genome profiling for re-biopsy of TKI resistant tumour
K. Kerr, GB

16:50 - 17:00 The perspective of the oncologist
E. Smit, NL

17:00 - 17:30 Discussion

16:30 - 18:00 Type: Educational session Stockholm
 Title: Advances in precision medicine of gastric cancer
 Chair(s): Y. Janjigian, US; Y.-K. Kang,

16:30 - 16:55 Genetic and immune signatures of gastric cancer to inform prognosis and clinical decision making
A. Hillmer, SG

16:55 - 17:20 Surgical precision: Novel techniques and perspectives
C. Mariette, FR

17:20 - 17:45 Novel drugs: More precise, more efficacious and safer?
Y. Janjigian, US

17:45 - 18:00 Conclusions and clinical perspectives
Y.-K. Kang,



16:30 - 18:00	Type: Special Symposium Title: Personalising treatment for sarcoma Chair(s): O. Mir, FR	Athens
16:30 - 16:35	Introduction	
16:35 - 16:50	Deep sequencing in sarcoma: The pathologist's perspective <u>A.P. Dei Tos</u> , IT	
16:50 - 17:05	Treatment according to histological subtypes <u>S. Stacchiotti</u> , IT	
17:05 - 17:20	Individualising radiation therapy (use / non-use) <u>R. Haas</u> , NL	
17:20 - 17:35	Molecular profiling for patients with STS <u>A. Italiano</u> , FR	
17:35 - 17:50	Personalising treatment of bone sarcoma <u>E. de Alava</u> , ES	
17:50 - 18:00	Conclusions and clinical perspectives <u>O. Mir</u> , FR	
16:30 - 18:00	Type: Proffered Paper session Title: Proffered papers session 15	Helsinki
16:30 - 17:30	Type: Poster Discussion session Title: Poster discussion session 5	Brussels
16:30 - 17:30	Type: Poster Discussion session Title: Poster discussion session 6	Berlin
16:30 - 17:30	Type: Poster Discussion session Title: Poster discussion session 7	Bern
16:30 - 18:00	Type: Proffered Paper session Title: Proffered papers session 14	Oslo



18:00 - 19:30 Type: Patient Advocacy Track Zagreb
Title: Adherence

18:00 - 18:10 Why adherence matters

18:10 - 18:20 Do your patients really take their cancer drugs as prescribe: Learnings from the global CML adherence study

18:20 - 18:30 Adherence: The perspective of an oncologist

18:30 - 18:40 The influence of drug packaging on adherence

18:40 - 18:50 Continued Sharing Decision Making as a way to improve adherence

18:50 - 19:30 Discussion

18:30 - 20:00 Type: Industry Satellite Symposium Stockholm
Title: Industry Satellite Symposium or ESMO Colloquium

18:30 - 20:00 Type: Industry Satellite Symposium Madrid
Title: Industry Satellite Symposium or ESMO Colloquium

18:30 - 20:00 Type: Industry Satellite Symposium Rome
Title: Industry Satellite Symposium or ESMO Colloquium

18:30 - 20:00 Type: Industry Satellite Symposium Athens
Title: Industry Satellite Symposium or ESMO Colloquium

18:30 - 20:00 Type: Industry Satellite Symposium Helsinki
Title: Industry Satellite Symposium or ESMO Colloquium

18:30 - 20:00 Type: Industry Satellite Symposium Brussels
Title: Industry Satellite Symposium or ESMO Colloquium

18:30 - 20:00 Type: Industry Satellite Symposium Oslo
Title: Industry Satellite Symposium or ESMO Colloquium

09-10-2016



08:00 - 09:00 Type: Challenge Your Expert (CYE) session Athens
Title: Will there be a place for adoptive T-cell therapy in the checkpoint inhibitors?

08:00 - 08:30 Will there be a place for adoptive T-cell therapy in the checkpoint inhibitors?
J. Schachter, IL

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Helsinki
Title: Management of poor risk germ cell tumours

08:00 - 08:30 Management of poor risk germ cell tumours
C. Kollmannsberger, CA

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Brussels
Title: Challenges in pancreatic cancer

08:00 - 08:30 Challenges in pancreatic cancer
M. Hidalgo, ES

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Berlin
Title: What is the clinical utility of gene expression-based tests in early breast cancer?

08:00 - 08:30 What is the clinical utility of gene expression-based tests in early breast cancer?
A. Prat, ES

08:30 - 09:00 Discussion

08:15 - 09:15 Type: Controversy session Rome
Title: Controversy session 3



09:00 - 10:30	Type: Special Symposium Title: New molecular challenges in CRC Chair(s): S. Tejpar, BE; P. Pfeiffer, DK	Copenhagen
09:00 - 09:05	Introduction <u>P. Pfeiffer</u> , DK	
09:05 - 09:20	New classification of CRC: "Gone molecular"? <u>D. Aust</u> , DE	
09:20 - 09:35	Liquid biopsies: Ever closer to daily practice? <u>P. Laurent-Puig</u> , FR	
09:35 - 09:50	BRAF mutations: What are the treatment options? <u>F. Loupakis</u> , IT	
09:50 - 10:05	Patients with rare mutations: Do they need a precision approach? <u>S. Siena</u> , IT	
10:05 - 10:20	Immunotherapy in mCRC: MSI and beyond <u>N. Segal</u> , US	
10:20 - 10:30	Conclusions and clinical perspectives <u>S. Tejpar</u> , BE	
09:00 - 10:30	Type: Educational session Title: Upgrading your knowledge on how drug development works nowadays Chair(s): U. Banerji, GB	Madrid
09:00 - 09:30	Defining the right dose: When and how <u>J. Schellens</u> , NL	
09:30 - 10:00	To test or not to test: The role of biomarkers in assisting drug development <u>U. Banerji</u> , GB	
10:00 - 10:30	New side effects of novel drugs that you should be aware of <u>D. Tan</u> , SG	



09:00 - 10:30	Type: Special Symposium Title: Translating tumour biology into novel therapeutic approaches in HNSCC Chair(s): R.L. Ferris, US	Oslo
09:00 - 09:05	Introduction	
09:05 - 09:25	Targeting tumour hypoxia <u>V. Grégoire</u> , BE	
09:25 - 09:45	Comparison of the genetic landscape of HPV+ and HPV- head and neck cancers <u>P. Brennan</u> , FR	
09:45 - 10:05	The role of immunotherapy in HNSCC <u>R.L. Ferris</u> , US	
10:05 - 10:25	Novel therapeutic strategies in EBV associated NPC <u>A.T.C. Chan</u> , CN	
10:25 - 10:30	Conclusions and clinical perspectives <u>R.L. Ferris</u> , US	
09:15 - 10:45	Type: Patient Advocacy Track Title: Adaptive licensing (MAPPs)	Zagreb
09:15 - 09:30	Introduction	
09:30 - 09:45	Regulatory perspectives in MAPPs and the EMA pilot	
09:45 - 10:00	MAPPs from the HTA perspective	
10:00 - 10:15	A clinician's perspective: Learning from the rare disease community	
10:15 - 10:30	The patient perspective: Patientcentric drug development	
10:30 - 10:45	Discussion: Challenges	



09:30 - 10:30	Type: Multidisciplinary patient cases Title: Can immunotherapy be given safely to special subtypes of patients? Chair(s): P. Nathan, GB	Vienna
09:30 - 09:40	Autoimmunity and cancer immunotherapy <u>P. Nathan</u> , GB	
09:40 - 09:50	Brain metastases and cancer immunotherapy <u>P. Ascierto</u> , IT	
09:50 - 10:00	Chronic viral infections and cancer immunotherapy	
10:00 - 10:30	Discussion	
09:30 - 10:30	Type: Multidisciplinary patient cases Title: How to approach a patient with oligometastatic NSCLC Chair(s): M. Ahmed, GB	Stockholm
09:30 - 09:40	A simple case <u>M. Ahmed</u> , GB	
09:40 - 09:50	A difficult case <u>N. Reinmuth</u> , DE	
09:50 - 10:00	An impossible case <u>J.B. Soerensen</u> , DK	
10:00 - 10:30	Discussion	
09:30 - 10:30	Type: Controversy session Title: Controversy session 4	Rome



09:30 - 10:30	Type: Multidisciplinary patient cases Title: CNS Lymphoma Chair(s): F. Graus, ES	Athens
09:30 - 09:40	Primary CNS lymphoma <u>F. Graus</u> , ES	
09:40 - 09:50	Secondary CNS lymphoma <u>A. Ferreri</u> , IT	
09:50 - 10:30	Discussion	
09:30 - 10:30	Type: Challenge Your Expert (CYE) session Title: BRCA testing in ovarian cancer: Who, why, when and how	Helsinki
09:30 - 09:50	BRCA testing to drive therapy in ovarian cancer <u>E. Pujade-Lauraine</u> , FR	
09:50 - 10:10	BRCA testing and prevention in ovarian cancer <u>J. Balmaña</u> , ES	
10:10 - 10:30	Discussion	
09:30 - 10:30	Type: Poster Discussion session Title: Poster discussion session 8	Brussels
09:30 - 10:30	Type: Poster Discussion session Title: Poster discussion session 9	Berlin
10:45 - 12:45	Type: ESMO Clinical Practice Guidelines session Title: ESMO Clinical Practice Guidelines session 1	Rome
11:00 - 12:30	Type: Proffered Paper session Title: Proffered papers session 16	Copenhagen
11:00 - 12:30	Type: Proffered Paper session Title: Proffered papers session 17	Vienna



11:00 - 12:30	Type: Special Symposium Title: Treatment options in patients with early breast cancer and BRCA mutation or family history of cancer Chair(s): A. Tutt, GB; H. Bonnefoi, FR	Stockholm
11:00 - 11:05	Introduction <u>H. Bonnefoi</u> , FR	
11:05 - 11:25	Surgical options <u>M. Menke-Pluijmers</u> , NL	
11:25 - 11:45	Systemic therapy <u>A. Tutt</u> , GB	
11:45 - 12:05	Patient's preference <u>K. Benn</u> , GB	
12:05 - 12:25	Fertility issues <u>H.A. Azim, Jr.</u> , BE	
12:25 - 12:30	Conclusions and clinical perspectives <u>A. Tutt</u> , GB	
11:00 - 12:30	Type: Educational session Title: Multimodality treatment for hormone-naïve metastatic prostate cancer	Madrid
11:00 - 11:30	Docetaxel for prostate cancer: Best timing and right patient	
11:30 - 12:00	Radiation to the primary tumour in metastatic disease: When and whom <u>A. Bossi</u> , GB	
12:00 - 12:30	Does radical prostatectomy have an impact on long-term outcomes of patients with metastatic prostate cancer? <u>A. Heidenreich</u> , DE	
11:00 - 12:30	Type: Special Session Title: Financing immunotherapeutic drugs across Europe and how to get these drugs to our patients	Athens



11:00 - 12:00 Type: Multidisciplinary patient cases Helsinki
 Title: Systemic treatment for atypical GIST patients

11:00 - 11:10 Frail elderly
 R. Jones, GB

11:10 - 11:20 Drug interactions
 O. Mir, FR

11:20 - 11:30 Local treatments in oligometastatic disease
 A. Gronchi, IT

11:30 - 12:00 Discussion

11:00 - 12:30 Type: Special Session Brussels
 Title: Practising quality oncology across Europe and beyond: How can we get there? Existing projects and future outlooks
 Chair(s): D. Arnold, DE; S. Rauh, LU

11:00 - 11:05 Introduction
 D. Arnold, DE

11:05 - 11:15 Quality improvement in centre structures. Experience within the German Cancer Society accreditation system
 J. Bruns, DE

11:15 - 11:25 What is meant by "quality in oncology care"?

11:25 - 11:35 Optimised management of lung cancers: an example for quality care management
 M. Saghatchian, FR

11:35 - 12:10 Round table panel discussion

12:10 - 12:25 Q&A

12:25 - 12:30 Conclusions
 S. Rauh, LU



11:00 - 12:30	Type: Special Symposium Title: Moving steps forward: What's new in the treatment of brain tumours Chair(s): P. Wen, US	Berlin
11:00 - 11:05	Introduction	
11:05 - 11:25	Immunotherapy for glioblastoma: Quo vadis? <u>M. Weller</u> , CH	
11:25 - 11:45	Identifying and overcoming challenges in immunotherapy for brain tumours: The iRANO approach <u>P. Wen</u> , US	
11:45 - 12:05	Targeting angiogenesis in high-grade gliomas: The long and winding road <u>E. Galanis</u> , US	
12:05 - 12:25	How can we deal with the toxicity of new agents? <u>D. Blumenthal</u> , IL	
12:25 - 12:30	Conclusions and clinical perspectives <u>P. Wen</u> , US	
11:00 - 12:00	Type: Poster Discussion session Title: Poster discussion session 10	Bern
11:00 - 12:00	Type: Young Oncologist Brunch Title: How to find the best literature for your paper: Pubmed and other academic databases Chair(s): M. Ozturk, TR; J. Corral, ES	Lisbon
11:00 - 11:25	How to find the best literature for your paper: Pubmed and other academic databases <u>E. Harriss</u> , GB	
11:25 - 12:00	Interactive discussion with audience	
11:00 - 12:30	Type: Joint Symposium Title: ESMO Joint Symposium 10	Oslo
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Oslo



13:00 - 13:45	Type: Keynote lecture Title: The art of the possible: Bridging the gap between genomics and patient care?	Vienna
13:00 - 13:45	The art of the possible: Bridging the gap between genomics and patient care? <u>E. Voest</u> , NL	
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Stockholm
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Madrid
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Athens
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Helsinki
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Brussels
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Berlin
13:00 - 14:30	Type: Patient Advocacy Track Title: Immune therapies	Zagreb
13:00 - 13:15	Introduction to immune therapies	
13:15 - 13:30	10 for IO: The IKCC experience	
13:30 - 13:45	Lecture to be defined	
13:45 - 14:00	Learning about immuno-oncology: The IO Portal	
14:00 - 14:30	Discussion: What can we as community do to increase the knowledge about immune therapies? How do we pick up side effects in our communities?	



14:15 - 17:15	Type: Young Oncologist Masterclass Title: Harnessing the immune system for cancer therapy Chair(s): R. Califano, GB; M. Preusser, AT	Bern
14:15 - 14:40	Basic immunology for the medical oncologist <u>I. Melero</u> , ES	
14:40 - 14:40	Session Shooter <u>L. De Mattos-Arruda</u> , ES	
14:40 - 14:55	Discussion	
14:55 - 15:20	Immune checkpoint blockade and impact on clinical practice <u>J. Wolchok</u> , US	
15:20 - 15:20	Session Shooter <u>J. Corral</u> , ES	
15:20 - 15:35	Discussion	
15:35 - 15:55	Break	
15:55 - 16:20	Combining immunotherapies with other anti-cancer therapies <u>P. Lorigan</u> , GB	
16:20 - 16:20	Session Shooter <u>M. Petrova</u> , BG	
16:20 - 16:35	Discussion	
16:35 - 17:00	Managing toxicities: Case based discussions <u>J. Weber</u> , US	
17:00 - 17:00	Session Shooter <u>R. De Mello</u> , PT	
17:00 - 17:15	Discussion	
14:30 - 16:30	Type: ESMO Clinical Practice Guidelines session Title: ESMO Clinical Practice Guidelines session 2	Rome



14:45 - 16:15	Type: Special Symposium Title: Triple negative breast cancer: Do we now have something to be positive about? Chair(s): E. Senkus, PL	Copenhagen
14:45 - 14:50	Introduction: The current landscape <u>E. Senkus</u> , PL	
14:50 - 15:10	Molecular "dissection" of TNBC to identify therapeutic targets <u>F. André</u> , FR	
15:10 - 15:30	Targeting DNA repair mechanisms <u>R. Dent</u> , SG	
15:30 - 15:50	Androgen receptor blockade <u>H. Bonnefoi</u> , FR	
15:50 - 16:10	Immunotherapeutic approaches <u>P. Schmid</u> , GB	
16:10 - 16:15	Concluding discussion	
14:45 - 16:15	Type: Special Symposium Title: Personalised medicine in gynaecological cancers Chair(s): A. Poveda, ES; C. Gourley, GB	Vienna
14:45 - 14:50	Introduction <u>A. Poveda</u> , ES	
14:50 - 15:10	Immunotherapy in ovarian cancer <u>L. Kandalaft</u> , CH	
15:10 - 15:30	Genomic profiling of endometrial cancer <u>H. Salvesen</u> , NO	
15:30 - 15:50	Genomic profiling of ovarian cancer <u>C. Gourley</u> , GB	
15:50 - 16:10	How to test and define HRD positive population in ovarian cancer <u>I. McNeish</u> , GB	
16:10 - 16:15	Conclusions and clinical perspectives <u>C. Gourley</u> , GB	



14:45 - 16:15	Type: Educational session Title: Melanoma: Does the run of success continue?	Stockholm
14:45 - 15:15	New checkpoints <u>J. Weber</u> , US	
15:15 - 15:45	Neoantigens	
15:45 - 16:15	Novel immunotherapeutic constructs (MuSK antibodies)	
14:45 - 16:15	Type: Proffered Paper session Title: Proffered papers session 18	Madrid
14:45 - 16:15	Type: Educational session Title: Induction chemotherapy: Is there any new data to revisit an inconclusive approach? Chair(s): M. Merlano, IT	Athens
14:45 - 15:15	New data from meta-analysis <u>W. Budach</u> , DE	
15:15 - 15:45	Emerging clinical trial data <u>M. Merlano</u> , IT	
15:45 - 16:15	Induction chemotherapy: Is there any new data from randomised trials to revisit an inconclusive approach? <u>J. Bourhis</u> , CH	
14:45 - 16:15	Type: Joint Symposium Title: ESMO Joint Symposium 11	Helsinki



14:45 - 16:15	Type: Educational session Title: Desmoid tumours in 2016 Chair(s): <u>D. Strauss</u> , GB	Brussels
14:45 - 15:15	Molecular pathology tools <u>F. Chibon</u> , FR	
15:15 - 15:45	Local treatments <u>D. Strauss</u> , GB	
15:45 - 16:15	Systemic treatments beyond chemotherapy and TKIs <u>B. Kasper</u> , DE	
15:00 - 16:00	Type: Poster Discussion session Title: Poster discussion session 11	Berlin
15:00 - 16:00	Type: Multidisciplinary patient cases Title: Biliary tract cancer: Klatskin tumour Chair(s): <u>M. Ducreux</u> , FR	Oslo
15:00 - 15:05	Case presentation <u>M. Ducreux</u> , FR	
15:05 - 15:15	The role of surgery and transplantation <u>R. Adam</u> , FR	
15:15 - 15:25	Medical treatment <u>M. Ducreux</u> , FR	
15:25 - 15:35	Radiation	
15:35 - 16:00	Discussion	
16:30 - 18:00	Type: Late-Breaking Abstracts Title: Late-Breaking abstracts session	Copenhagen



16:30 - 17:30	Type: Multidisciplinary patient cases Title: Continuum of management of stage IV in melanoma Chair(s): O. Michielin, CH	Vienna
16:30 - 16:40	First-line <u>C. Blank</u> , NL	
16:40 - 16:50	Second-line <u>C. Hoeller</u> , AT	
16:50 - 17:00	Brain metastasis <u>L. Bastholt</u> , DK	
17:00 - 17:30	Discussion	
16:30 - 18:00	Type: Educational session Title: Prophylaxis and treatment of symptoms in oncology Chair(s): F. Roila, IT; K. Jordan, DE	Stockholm
16:30 - 17:00	Chemotherapy induced nausea and vomiting focusing on the updated MASCC/ESMO guidelines <u>K. Jordan</u> , DE	
17:00 - 17:30	Diagnosis and therapy of patients with febrile neutropenia <u>G. Maschmeyer</u> , DE	
17:30 - 18:00	Assessment and therapy of anxiety and depression <u>J.H. Loge</u> , NO	
16:30 - 17:30	Type: Poster Discussion session Title: Poster discussion session 12	Athens



16:30 - 18:00	Type: Educational session Title: Bad luck or bad knowledge? Evidence-based cancer prevention approaches Chair(s): J. Cuzick, GB	Helsinki
16:30 - 17:00	Where to give prevention advice	
17:00 - 17:30	Proven interventions <u>S. Franceschi</u> , FR	
17:30 - 18:00	Unproven interventions	
16:30 - 17:30	Type: Poster Discussion session Title: Poster discussion session 13	Brussels
16:30 - 17:30	Type: Poster Discussion session Title: Poster discussion session 14	Berlin
16:30 - 18:00	Type: Special Symposium Title: Precision medicine in NETs: Myth or reality? Chair(s): R. Garcia-Carbonero, ES; K. Oeberg, SE	Oslo
16:30 - 16:35	Introduction <u>R. Garcia-Carbonero</u> , ES	
16:35 - 16:50	Molecular tumour profiling and upcoming biomarkers: Will they help to deliver personalised medicine? <u>T. Meyer</u> , GB	
16:50 - 17:05	Minimally invasive surgery: Does it improve precision? <u>M. Falconi</u> , IT	
17:05 - 17:20	Nuclear medicine: What do novel isotopes add to the treatment of NETs? <u>D. Kwekkeboom</u> , NL	
17:20 - 17:35	Targeted drugs: Where are we now? <u>M. Pavel</u> , DE	
17:35 - 17:50	Targeted drugs: Where are we heading to? <u>E. Raymond</u> , CH	
17:50 - 18:00	Conclusions and clinical perspectives <u>K. Oeberg</u> , SE	



16:45 - 17:45	Type: Controversy session Title: Controversy session 5	Rome
17:30 - 18:45	Type: Young Oncologist Vesalius Talk Title: Young Oncologists Vesalius Talk Chair(s): F. Ciardiello, IT	Lisbon
17:30 - 17:50	Developing an effective relationship between basic scientists and medical oncologists <u>F. Ciardiello</u> ¹ , <u>R. Marais</u> ² , <u>M. Sibilio</u> ³ , <u>M. Garassino</u> ¹ ; ¹ IT, ² GB, ³ AT	
18:00 - 19:30	Type: Patient Advocacy Track Title: Patients reporting their side effects	Zagreb
18:00 - 18:15	New drugs that are safe: Pharmacovigilance in oncology	
18:15 - 18:30	It depends on your point of view: How patients, carers, nurses and clinicians perceive side effects	
18:30 - 18:45	Ask the specialist: Patients directly reporting their side effects	
18:45 - 19:00	Patient networks increasing AE reporting The UMC/ MPNE project	
19:00 - 19:30	Discussion: what can we as patient advocates do to - increase the safety of our therapies? - ensure that side effects are evaluated according to the true impact for patients?	
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Stockholm
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Madrid
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Rome
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Athens
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Helsinki



18:30 - 20:00 Type: Industry Satellite Symposium
Title: Industry Satellite Symposium or ESMO Colloquium Brussels

18:30 - 20:00 Type: Industry Satellite Symposium
Title: Industry Satellite Symposium or ESMO Colloquium Oslo

10-10-2016

08:00 - 09:00 Type: Challenge Your Expert (CYE) session
Title: Synchronous metastatic colorectal cancer: Addressing difficult situations Rome

08:00 - 08:30 Synchronous metastatic colorectal cancer: Addressing difficult situations
G. Folprecht, DE

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session
Title: Lights and shadows in targeting KRAS driven lung cancer Athens

08:00 - 08:30 Lights and shadows in targeting KRAS driven lung cancer
P. Jänne, US

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session
Title: Are guidelines necessary for everyday treatment in metastatic breast cancer? Brussels

08:00 - 08:30 Are guidelines necessary for everyday treatment in metastatic breast cancer?
F. Cardoso, PT

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session
Title: Management of side effects Berlin

08:00 - 08:30 Management of side effects
G. Long, AU

08:30 - 09:00 Discussion



08:00 - 09:00 Type: Challenge Your Expert (CYE) session Bern
Title: Management of sinonasal tumours

08:00 - 08:30 Management of sinonasal tumours
L. Licitra, IT

08:30 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Lisbon
Title: The development of novel anticancer drugs: How to raise the bar in oncology

08:00 - 08:30 The development of novel anticancer drugs: How to raise the bar in oncology
A. Sobrero, IT

08:30 - 09:00 Discussion

09:00 - 10:30 Type: Joint Symposium Oslo
Title: ESMO Joint Symposium 12

09:00 - 10:30 Type: Educational session Vienna
Title: Advances in targeted therapy in gynaecological cancers
Chair(s): M. Mirza, DK; J. Ledermann, GB

09:00 - 09:30 Positioning anti-angiogenic therapy in the ovarian cancer treatment pathway
P. Harter, DE

09:30 - 10:00 PARP inhibitors in ovarian cancer: What are the next steps?
J. Ledermann, GB

10:00 - 10:30 Cervical cancer therapy in 2016
M. Mirza, DK



09:00 - 10:30	Type: Special Symposium Title: Biomarker strategies to improve the treatment of castration-resistant prostate cancer Chair(s): D. Olmos, ES	Madrid
09:00 - 09:05	Introduction	
09:05 - 09:25	Translating the genomics landscape into clinical practice <u>R. Bristow</u> , CA	
09:25 - 09:45	What is the role of CTCs? <u>H. Scher</u> , US	
09:45 - 10:05	Using circulating tumour DNA studies to improve the management of prostate cancer patients <u>G. Attard</u> , GB	
10:05 - 10:25	Molecularly defining neuroendocrine prostate cancer <u>H. Beltran</u> , US	
10:25 - 10:30	Conclusions and clinical perspectives	
09:15 - 10:45	Type: Proffered Paper session Title: Proffered papers session 19	Copenhagen



09:15 - 10:45	Type: Special Symposium Title: Clinical challenges and patient needs based on defined supportive and palliative interventions delivered by competent multidisciplinary professionals Chair(s): F. Scotté, FR; F. Strasser, CH	Rome
09:15 - 09:20	Introduction	
09:20 - 09:40	Integrated care pathways <u>S. Kaasa</u> , NO	
09:40 - 10:00	Evidence-based supportive care interventions <u>J. Herrstedt</u> , DK	
10:00 - 10:20	Evidence-based palliative care interventions <u>F. Strasser</u> , CH	
10:20 - 10:40	Utilising the available multidisciplinary and interprofessional work force for optimal patient care <u>D. Keefe</u> , AU	
10:40 - 10:45	Conclusions and clinical perspectives	
09:15 - 10:45	Type: Educational session Title: Rare lymphomas: Recent developments in diagnostic and treatment Chair(s): A. Lopez-Guillermo, ES; C. Thieblemont, FR	Athens
09:15 - 09:45	Enteropathy associated lymphoma <u>O. Visser</u> , NL	
09:45 - 10:15	Marginal zone lymphoma <u>C. Thieblemont</u> , FR	
10:15 - 10:45	Waldenström's macroglobulinemia <u>M. Dimopoulos</u> , GR	



09:30 - 10:30	Type: Multidisciplinary patient cases Title: Treatment approaches in elderly patients Chair(s): S. Monfardini, IT	Stockholm
09:30 - 09:35	Case presentation <u>S. Monfardini</u> , IT	
09:35 - 09:45	Bringing geriatrics into oncology <u>S. Monfardini</u> , IT	
09:45 - 09:55	Tailoring local treatment to the elderly <u>I. Kunkler</u> , GB	
09:55 - 10:05	Optimising systemic therapy <u>H. Wildiers</u> , BE	
10:05 - 10:30	Discussion	
09:30 - 10:30	Type: Multidisciplinary patient cases Title: Targeting the genes is not enough: The patients and tumour behaviour also matter Chair(s): P. Jänne, US	Helsinki
09:30 - 09:40	One mutation, many cancers <u>D. Huntsman</u> , CA	
09:40 - 09:50	Resistance mutations and cell context specific adaptive responses <u>P. Jänne</u> , US	
09:50 - 10:00	Considering clonal evolution in breast cancer management <u>C. Caldas</u> , GB	
10:00 - 10:30	Discussion	
09:30 - 10:30	Type: Poster Discussion session Title: Poster discussion session 15	Brussels



09:30 - 10:30	Type: Challenge Your Expert (CYE) session Title: Genetic essentials for the modern practicing oncologist	Berlin
09:30 - 10:00	Genetic essentials for modern practicing oncologist <u>E. Voest</u> , NL	
10:00 - 10:30	Discussion	
09:30 - 10:30	Type: Challenge Your Expert (CYE) session Title: What are genomics adding to patient management?	Bern
09:30 - 10:00	What are genomics adding to patient management? <u>J. Bertherat</u> , FR	
10:00 - 10:30	Discussion	
09:30 - 10:30	Type: Young Oncologist Mentorship session Title: ESMO Young Oncologists Mentorship session Chair(s): M. Strijbos, BE; C. Qvortrup, DK	Lisbon
09:30 - 10:30	Working in academia - Table 1 <u>R. Stupp</u> , CH	
10:30 - 11:30	Working in academia - Table 2 <u>E. Felip</u> , ES	
11:30 - 12:30	Practicing oncologists - Table 1 <u>S. Braga</u> , PT	
12:30 - 13:30	Practicing oncologists - Table 2	
13:30 - 14:30	Industry as a career choice - Table 1 <u>T. Lillie</u> , GB	
14:30 - 15:30	Industry as a career choice - Table 2 <u>M. Rashford</u> , FR	
11:00 - 12:30	Type: Proffered Paper session Title: Proffered papers session 20	Copenhagen



11:00 - 12:00 Type: Multidisciplinary patient cases Vienna
 Title: Liver dominant disease
 Chair(s): T. Gruenberger, AT

11:00 - 11:10 Is the potential of cure adequately depicted within tumour boards?
T. Gruenberger, AT

11:10 - 11:20 What is the best induction, and which post-op therapies should be used?
C.-H. Koehne, DE

11:20 - 11:30 Radiofrequency and intra-arterial treatments: How to place them
T. de Baere, FR

11:30 - 12:00 Discussion

11:00 - 12:30 Type: Special Symposium Stockholm
 Title: Immunotherapy in GU malignancies
 Chair(s): J. Bellmunt, US; M. Schmidinger, AT

11:00 - 11:05 Introduction
J. Bellmunt, US

11:05 - 11:25 Biology and new immunological targets in GU malignancies
J. Haanen, NL

11:25 - 11:45 Biomarkers of response and progression in (GU) immunotherapy
T. Choueiri, US

11:45 - 12:05 Immunotherapy in urothelial cancers
J. Bellmunt, US

12:05 - 12:25 Immunotherapy in kidney cancer
L. Albiges, FR

12:25 - 12:30 Conclusions and clinical perspectives
M. Schmidinger, AT



11:00 - 12:00	Type: Multidisciplinary patient cases Title: Current options for recurrent platinum sensitive ovarian cancer Chair(s): A. Gonzalez Martin, ES	Madrid
11:00 - 11:05	Case presentation <u>A. Gonzalez Martin</u> , ES	
11:05 - 11:15	Surgery is an option in platinum sensitive recurrence <u>C. Marth</u> , AT	
11:15 - 11:25	How imaging can help select patients for optimal surgery <u>V. Vandecaveye</u> , BE	
11:25 - 11:35	Sensitive pop and systemic treatment: Which option for which patient? <u>A. Gonzalez Martin</u> , ES	
11:35 - 12:00	Discussion	
11:00 - 12:30	Type: Special Symposium Title: Using biomarkers to monitor the dynamics of tumour responses to therapy Chair(s): A. Sobrero, IT; J. Seoane, ES	Rome
11:00 - 11:05	Introduction <u>A. Sobrero</u> , IT	
11:05 - 11:25	Biomarkers of the host <u>G. Coukos</u> , CH	
11:25 - 11:45	Circulating biomarkers to monitor patient responses <u>C. Dive</u> , GB	
11:45 - 12:05	Patient derived models to select treatment <u>J. Seoane</u> , ES	
12:05 - 12:25	Using dynamic changes in inflammation to monitor tumour responses <u>P. Tumej</u> , US	
12:25 - 12:30	Conclusions and clinical perspectives <u>J. Seoane</u> , ES	
11:00 - 12:30	Type: Joint Symposium Title: ESMO Joint Symposium 13	Athens



11:00 - 12:30	Type: Special Symposium Title: Streamlining the equitable delivery of anti-cancer drugs: Sharing common grounds for a pan-European vision of value Chair(s): R. Giuliani, IT	Helsinki
11:00 - 11:05	Introduction	
11:05 - 11:20	Equitable and affordable cancer care: Is Europe a union for real? <u>R. Sullivan</u> , GB	
11:20 - 11:35	The European Commission's initiatives to reduce disparities in cancer care: The strategic role of HTA network <u>A. Rys</u> , BE	
11:35 - 11:50	The EMA's initiatives to speed up access to valuable cancer drugs: Adaptive pathways and flexible approaches <u>F. Pignatti</u> , GB	
11:50 - 12:05	Industry's initiatives to reduce inequities and increase access to valuable cancer care: Myth or reality? <u>R. Bergstrom</u> , BE	
12:05 - 12:20	ESMO's initiatives to reduce disparities in cancer care: Promoting access to valuable drugs focusing on the magnitude of benefit <u>E.G.E. de Vries</u> , NL	
12:20 - 12:30	Conclusions and clinical perspectives <u>R. Giuliani</u> , IT	
11:00 - 12:00	Type: Poster Discussion session Title: Poster discussion session 16	Brussels
11:00 - 12:00	Type: Poster Discussion session Title: Poster discussion session 17	Berlin



11:00 - 12:00	Type: Young Oncologist Brunch Title: What makes a good review article? The Editors perspective Chair(s): N. Volkov, RU	Lisbon
11:00 - 11:20	Original articles <u>O. Mir</u> , FR	
11:20 - 11:40	Review	
11:40 - 12:00	Interactive discussion with audience	
11:00 - 12:30	Type: Special Session Title: Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agents	Oslo
11:00 - 11:05	Introduction	
11:05 - 11:25	Developing drugs targeting the PI3K/AKT signalling	
11:25 - 11:45	Pembrolizumab (anti-PD1) in colorectal cancer	
11:45 - 12:05	Novel clinical trial designs incorporating genomics for developing anti-cancer drugs: Olaparib in prostate cancer	
12:05 - 12:25	The role of consortia and corporative groups in the modern era of cancer drug development	
12:25 - 12:30	Conclusions	
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Oslo
13:00 - 13:45	Type: Keynote lecture Title: The patient journey: Is cancer cure around the corner?	Vienna
13:00 - 13:45	The patient journey: Is cancer cure around the corner? <u>J.-C. Soria</u> , FR	



13:00 - 14:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Stockholm
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Madrid
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Rome
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Athens
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Helsinki
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Brussels
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Berlin
13:00 - 14:30	Type: Patient Advocacy Track Title: The best care for our patients	Zagreb
13:00 - 13:15	The early integration of supportive care	
13:15 - 13:30	The perspective of a palliative/ supportive care specialist	
13:30 - 13:45	Holistic care concepts	
13:45 - 14:00	The perspective of the practising oncologist	
14:00 - 14:30	Discussion: How can we ensure best care for our patients?	



14:15 - 15:45	Type: Young Oncologist Special session Title: ESMO Fellowships and Awards Chair(s): C. Zielinski, AT; M. Preusser, AT	Lisbon
14:15 - 14:20	Introduction <u>C. Zielinski</u> , AT	
14:20 - 14:35	The ESMO Fellowship Programme <u>V. Guarneri</u> , IT	
14:35 - 14:50	Practical tips from a former fellow <u>D. Kolarevic</u> , RS	
14:50 - 15:05	Best fellowship project 1	
15:05 - 15:20	Best fellowship project 2	
15:20 - 15:25	Conclusions <u>M. Preusser</u> , AT	
15:25 - 15:45	Awards: Presentation of the ESMO 2016 Fellows and 2015 Best Exam Award 2015	
14:30 - 15:00	Type: Patient Advocacy Track Title: Wrap up and closure	Zagreb
14:45 - 16:15	Type: Educational session Title: The earthquake of immunotherapy in lung cancer Chair(s): L. Paz-Ares, ES; S. Peters, CH	Copenhagen
14:45 - 15:10	Current results of immunotherapy in thoracic oncology <u>L. Paz-Ares</u> , ES	
15:10 - 15:30	Can we select the right patient for immunotherapy in NSCLC? The clinician's point of view <u>S. Novello</u> , IT	
15:30 - 15:50	Can we select the right patient for immunotherapy in NSCLC? The pathologist's point of view <u>M. Tsao</u> , CA	
15:50 - 16:15	Management of side effects of immunotherapy <u>M. Reck</u> , DE	



14:45 - 16:15 Type: Special Session Stockholm
 Title: Liquid biopsies
 Chair(s): R. Dziadziuszko, PL; P. Meldgaard, DK

14:45 - 14:50 Introduction

14:50 - 15:15 Solid tumour, liquid biopsy: Can blood samples give us the answers?
D.(-M. Lo, CN

15:15 - 15:40 Tracking changes: Monitoring evolution of disease through circulating free DNA
P. Meldgaard, DK

15:40 - 16:05 Blood-based tumour genomics: Technological advances
T. Würdinger, NL

16:05 - 16:15 Conclusions and clinical perspectives

14:45 - 16:15 Type: Educational session Madrid
 Title: Management of advanced radioactive-iodine (RAI) refractory differentiated thyroid cancer (DTC)
 Chair(s): J. Capdevila, ES; M. Schlumberger, FR

14:45 - 15:15 New insights in molecular biology of thyroid cancer
X. Matias-Guiu, ES

15:15 - 15:45 Enhancing iodine uptake in DTC

15:45 - 16:15 Treatment options in advanced RAI-refractory DTC
M. Schlumberger, FR



14:45 - 16:15	Type: Special Symposium Title: Drugs you will be using in 2020	Rome
14:45 - 14:50	Introduction	
14:50 - 15:05	Antibody-drug conjugates: Drones targeting tumours? <u>B. Fine</u> , US	
15:05 - 15:20	Engineered peptide therapeutics and other protein therapies <u>M. Stumpp</u> , CH	
15:20 - 15:35	Crafting selective and artisan kinase inhibitors <u>B. Hodous</u> , US	
15:35 - 15:50	Using viruses and bacteria to treat cancer <u>R. Alemany</u> , ES	
15:50 - 16:05	Genes to treat a genetic disease such as cancer: RNA therapeutics <u>P. Tassone</u> , IT	
16:05 - 16:15	Conclusions and clinical perspectives	
14:45 - 16:15	Type: Proffered Paper session Title: Proffered papers session 21	Athens
14:45 - 16:15	Type: Educational session Title: Straightforward options for earlier detection and treatment of challenging cancer types Chair(s): <u>H. de Koning</u> , NL	Helsinki
14:45 - 15:15	Review of all cancers <u>H. de Koning</u> , NL	
15:15 - 15:45	Ovarian cancer prevention: Are we finally there? <u>I. Jacobs</u> , AU	
15:45 - 16:15	Novel insights into Barrett's oesophagus <u>M. Di Pietro</u> , GB	
15:00 - 16:00	Type: Poster Discussion session Title: Poster discussion session 18	Brussels



15:00 - 16:00 Type: Poster Discussion session Berlin
Title: Poster discussion session 19

15:00 - 16:00 Type: Multidisciplinary patient cases Oslo
Title: Oligometastatic disease in prostate cancer patients
Chair(s): R. de Wit, NL

15:00 - 15:10 Radiation with curative intent
P. Ost, BE

15:10 - 15:20 Radical surgical intervention
S. Joniau, BE

15:20 - 15:30 Systemic treatments
R. de Wit, NL

15:30 - 16:00 Discussion

15:00 - 16:00 Type: Multidisciplinary patient cases Vienna
Title: Special situations in advanced breast cancer: De novo and limited metastatic disease
Chair(s): P.F. Conte, IT

15:00 - 15:10 Management of brain metastases in breast cancer
N. Lin, US

15:10 - 15:15 Case presentation
P.F. Conte, IT

15:15 - 15:25 Local therapy approaches
I. Kunkler, GB

15:25 - 15:35 Systemic therapy approaches
P.F. Conte, IT

15:35 - 16:00 Discussion



16:00 - 17:30	Type: Young Oncologist Forum Title: Professional development and communication skills Chair(s): L. De Mattos-Arruda, ES; S. Banerjee, GB	Lisbon
16:00 - 16:25	Presentation skills and dealing with media <u>D. Hart</u> , GB	
16:25 - 16:45	Interactive discussion with audience <u>M. Petrova</u> , BG	
16:45 - 17:10	How to become an effective leader and create a strong team <u>E. Martinelli</u> ¹ , <u>E. de Azambuja</u> ² ; ¹ IT, ² BE	
17:10 - 17:30	Interactive discussion with audience <u>C. Qvortrup</u> , DK	
16:30 - 18:00	Type: Presidential Symposium Title: Presidential Symposium 2	Copenhagen
16:30 - 18:00	Type: Educational session Title: Next generation small molecule inhibitors Chair(s): E. Smit, NL; T.S.K. Mok, CN	Vienna
16:30 - 17:00	Third generation EGFR TKI's <u>T.S.K. Mok</u> , CN	
17:00 - 17:30	Novel ALK inhibitors <u>S. Peters</u> , CH	
17:30 - 18:00	Novel targets in NSCLC and the compounds to combat them <u>G.J. Riely</u> , US	



16:30 - 18:00	Type: Educational session Title: HER2+ advanced breast cancer: A few more questions and many more answers Chair(s): J. Cortes, ES	Stockholm
16:30 - 17:00	Individualising first line treatment options for HER2+ metastatic breast cancer <u>H. Joensuu</u> , FI	
17:00 - 17:30	Second line, salvage and emerging treatments for HER2+ disease <u>J. Cortes</u> , ES	
17:30 - 18:00	The role of the immune response in HER2+ disease: Is it relevant for patient care? <u>S. Loi</u> , AU	
16:30 - 18:00	Type: Proffered Paper session Title: Proffered papers session 22	Madrid
16:30 - 18:00	Type: Proffered Paper session Title: Proffered papers session 24	Rome
16:30 - 17:30	Type: Multidisciplinary patient cases Title: HPV positive oropharynx cancer Chair(s): D. Rischin, AU	Athens
16:30 - 16:40	Early stage HPV positive OPC patient <u>C. Simon</u> , CH	
16:40 - 16:50	Locally advanced HPV positive OPC: Selection of deintensification candidates and deintensification strategies <u>D. Rischin</u> , AU	
16:50 - 17:30	Discussion	
16:30 - 18:00	Type: Proffered Paper session Title: Proffered papers session 25	Helsinki
16:30 - 17:30	Type: Poster Discussion session Title: Poster discussion session 20	Brussels
16:30 - 18:00	Type: Proffered Paper session Title: Proffered papers session 26	Bern
16:30 - 18:00	Type: Proffered Paper session Title: Proffered papers session 23	Oslo



18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Madrid
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Athens
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Helsinki
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Brussels
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Berlin
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Oslo
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium or ESMO Colloquium	Rome

11-10-2016



09:00 - 12:20	Type: Congress highlights Title: Congress Highlights Session 1 – The best of the ESMO 2016 Congress Chair(s): A. Cervantes, ES; F. Ciardiello, IT	Copenhagen
09:00 - 09:30	Breast cancer <u>R. Coleman</u> , GB	
09:30 - 09:50	Basic science and translational research <u>G. Ramaswamy</u> , US	
09:50 - 10:10	CNS tumours <u>E. Franceschi</u> , IT	
10:10 - 10:30	NETs and endocrine tumours <u>J. Valle</u> , GB	
10:30 - 10:50	Break	
10:50 - 11:10	GU prostate <u>E. Efstathiou</u> , US	
11:10 - 11:30	GU non-prostate <u>A. Necchi</u> , IT	
11:30 - 12:00	Thoracic malignancies <u>D. De Ruyscher</u> , BE	
12:00 - 12:20	Developmental therapeutics <u>C. Twelves</u> , GB	



09:00 - 12:30	Type: Congress highlights Title: Congress Highlights Session 2 – The best of the ESMO 2016 Congress Chair(s): A. Sobrero, IT; J. Tabernero, ES	Vienna
09:00 - 09:30	GI tumours <u>J. Taieb</u> , FR	
09:30 - 09:50	Sarcoma <u>S. Bauer</u> , DE	
09:50 - 10:10	Gynaecological cancers <u>C. Sessa</u> , CH	
10:10 - 10:30	Supportive and palliative care <u>F. Scotté</u> , FR	
10:30 - 10:50	Break	
10:50 - 11:10	Immunotherapy of cancer <u>J. Haanen</u> , NL	
11:10 - 11:30	Melanoma and other skin tumours <u>R. Dummer</u> , CH	
11:30 - 11:50	Head and neck cancer <u>A. Psyrri</u> , GR	
11:50 - 12:10	Public health and health economics <u>R. Giuliani</u> , IT	
12:10 - 12:30	Haematological malignancies <u>S. Le Gouill</u> , FR	